SHIVA GUPTA to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications SHIVA GUPTA has written about Xenograft Model Antitumor Assays.
Connection Strength
0.414
-
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clin Cancer Res. 2024 Aug 01; 30(15):3287-3297.
Score: 0.128
-
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther. 2017 11; 363(2):136-147.
Score: 0.079
-
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst. 2016 May; 108(5).
Score: 0.070
-
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res. 2014 Jul 15; 20(14):3730-41.
Score: 0.063
-
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. J Pharmacol Exp Ther. 2021 12; 379(3):343-357.
Score: 0.026
-
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res. 2017 01 01; 77(1):198-206.
Score: 0.019
-
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res. 2015 Apr 15; 21(8):1916-24.
Score: 0.016
-
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res. 2012 Aug 01; 18(15):4070-9.
Score: 0.014